Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Bausch Health Companies Inc.BHC · Entity 4363 | Director | June 24, 2022 | June 28, 2022 |
| REGENXBIO Inc.RGNX · Entity 2211 | Director | May 29, 2026 | June 02, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Bausch Health Companies Inc.
Report date June 24, 2022 · Filed June 28, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Shares, No Par ValueSEC Table I · non-derivative | Direct | 123,715 |
Reported balance
After 2022-06-24 transaction · row 1
1 source rowRow 1 · 2022-06-24 · Grant · Acquired 34,387 · Balance 123,715 F1: Represents the award of restricted share units ("RSUs") granted to non-employee directors of the Issuer on the third business day following their election at the Issuer's Annual Meeting of Shareholders. The RSUs have a grant date value equal to $250,000, vest immediately prior to the Issuer's next Annual Meeting of Shareholders, and are settled in common shares, no par value, of the Issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the award of restricted share units ("RSUs") granted to non-employee directors of the Issuer on the third business day following their election at the Issuer's Annual Meeting of Shareholders. The RSUs have a grant date value equal to $250,000, vest immediately prior to the Issuer's next Annual Meeting of Shareholders, and are settled in common shares, no par value, of the Issuer.
REGENXBIO Inc.
Report date May 29, 2026 · Filed June 02, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 28,861 |
Reported balance
After 2026-05-29 transaction · row 1
1 source rowRow 1 · 2026-05-29 · Grant · Acquired 9,807 · Balance 28,861 F1: Represents shares of common stock underlying a time-based restricted stock unit award (RSU). 100% of the shares subject to this RSU will vest on May 29, 2027 subject to the continuous service of the recipient to the Issuer. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.01 · Expires 2036-05-29 | Direct | 46,600 |
Reported balance
After 2026-05-29 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-05-29 · Grant · Acquired 46,600 · Balance 46,600 F2: The option will vest in 12 equal monthly installments following May 29, 2027 subject to the continuous service of the optionee to the Issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares of common stock underlying a time-based restricted stock unit award (RSU). 100% of the shares subject to this RSU will vest on May 29, 2027 subject to the continuous service of the recipient to the Issuer.
F2: The option will vest in 12 equal monthly installments following May 29, 2027 subject to the continuous service of the optionee to the Issuer.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 29, 2026 Filed Jun 2, 2026 21:16 UTC | REGENXBIO Inc. RGNX · Entity 2211 | GrantStock Options (Right to Buy) · Derivative | 46,600 | $0.00 Strike: $7.01 | $0.00 |
DisclosureSEC source: 0001191229-26-000002 · primarydocument.xml · derivative · entry 2 KARABELAS ARGERIS N · CIK 0001191229 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 46,600 Underlying: Common Stock · 46,600 shares Expires 2036-05-29 F2 · derivative.exercise_date: The option will vest in 12 equal monthly installments following May 29, 2027 subject to the continuous service of the optionee to the Issuer. Read SEC document |
| May 29, 2026 Filed Jun 2, 2026 21:16 UTC | REGENXBIO Inc. RGNX · Entity 2211 | GrantCommon Stock | 9,807 | $0.00 | $0.00 |
DisclosureSEC source: 0001191229-26-000002 · primarydocument.xml · nonDerivative · entry 1 KARABELAS ARGERIS N · CIK 0001191229 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,861 F1 · shares: Represents shares of common stock underlying a time-based restricted stock unit award (RSU). 100% of the shares subject to this RSU will vest on May 29, 2027 subject to the continuous service of the recipient to the Issuer. Read SEC document |
| May 30, 2025 Filed Jun 3, 2025 20:31 UTC | REGENXBIO Inc. RGNX · Entity 2211 | GrantStock Options (Right to Buy) · Derivative | 39,815 | $0.00 Strike: $8.85 | $0.00 |
DisclosureSEC source: 0001562180-25-004348 · primarydocument.xml · derivative · entry 2 KARABELAS ARGERIS N · CIK 0001191229 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,815 Underlying: Common Stock · 39,815 shares Expires 2035-05-30 F2 · derivative.exercise_date: The option will vest in 12 equal monthly installments following May 30, 2025 subject to the continuous service of the optionee to the Issuer. Read SEC document |
| May 30, 2025 Filed Jun 3, 2025 20:31 UTC | REGENXBIO Inc. RGNX · Entity 2211 | GrantCommon Stock | 7,768 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-25-004348 · primarydocument.xml · nonDerivative · entry 1 KARABELAS ARGERIS N · CIK 0001191229 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,054 F1 · shares: Represents shares of common stock underlying a time-based restricted stock unit award (RSU). 100% of the shares subject to this RSU will vest on May 1, 2026 subject to the continuous service of the recipient to the Issuer. Read SEC document |
| October 01, 2024 Filed Oct 2, 2024 20:31 UTC | REGENXBIO Inc. RGNX · Entity 2211 | Exercise / conversionStock Options (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $3.76 | $0.00 |
DisclosureSEC source: 0001562180-24-007144 · primarydocument.xml · derivative · entry 3 KARABELAS ARGERIS N · CIK 0001191229 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires 2025-05-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The previously granted option, representing a right to purchase a total of 40,000 shares, became exercisable as follows: 25% of the shares subject to the option vested on May 19, 2015, and the balance vested equal installments over the next 24 months. Read SEC document |
| October 01, 2024 Filed Oct 2, 2024 20:31 UTC | REGENXBIO Inc. RGNX · Entity 2211 | SaleCommon Stock | 10,000 | $10.11 | $101,052.00 |
DisclosureSEC source: 0001562180-24-007144 · primarydocument.xml · nonDerivative · entry 2 KARABELAS ARGERIS N · CIK 0001191229 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 11,286 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $10.01 to $10.35. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| October 01, 2024 Filed Oct 2, 2024 20:31 UTC | REGENXBIO Inc. RGNX · Entity 2211 | Exercise / conversionCommon Stock | 10,000 | $3.76 | $37,600.00 |
DisclosureSEC source: 0001562180-24-007144 · primarydocument.xml · nonDerivative · entry 1 KARABELAS ARGERIS N · CIK 0001191229 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 21,286 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| September 03, 2024 Filed Sep 5, 2024 00:20 UTC | REGENXBIO Inc. RGNX · Entity 2211 | Exercise / conversionStock Options (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $3.76 | $0.00 |
DisclosureSEC source: 0001562180-24-006657 · primarydocument.xml · derivative · entry 4 KARABELAS ARGERIS N · CIK 0001191229 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2025-05-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The previously granted option, representing a right to purchase a total of 40,000 shares, became exercisable as follows: 25% of the shares subject to the option vested on May 19, 2015, and the balance vested equal installments over the next 24 months. Read SEC document |
| September 03, 2024 Filed Sep 5, 2024 00:20 UTC | REGENXBIO Inc. RGNX · Entity 2211 | SaleCommon Stock | 700 | $12.34 | $8,638.00 |
DisclosureSEC source: 0001562180-24-006657 · primarydocument.xml · nonDerivative · entry 3 KARABELAS ARGERIS N · CIK 0001191229 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 11,286 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F3 · price: This transaction was executed in multiple trades at prices ranging from $12.24 to $12.53. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| September 03, 2024 Filed Sep 5, 2024 00:20 UTC | REGENXBIO Inc. RGNX · Entity 2211 | SaleCommon Stock | 9,300 | $11.50 | $106,950.00 |
DisclosureSEC source: 0001562180-24-006657 · primarydocument.xml · nonDerivative · entry 2 KARABELAS ARGERIS N · CIK 0001191229 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 11,986 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $11.24 to $12.20. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| September 03, 2024 Filed Sep 5, 2024 00:20 UTC | REGENXBIO Inc. RGNX · Entity 2211 | Exercise / conversionCommon Stock | 10,000 | $3.76 | $37,600.00 |
DisclosureSEC source: 0001562180-24-006657 · primarydocument.xml · nonDerivative · entry 1 KARABELAS ARGERIS N · CIK 0001191229 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 21,286 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| August 01, 2024 Filed Aug 5, 2024 22:39 UTC | REGENXBIO Inc. RGNX · Entity 2211 | Exercise / conversionStock Options (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $3.76 | $0.00 |
DisclosureSEC source: 0001562180-24-006015 · primarydocument.xml · derivative · entry 7 KARABELAS ARGERIS N · CIK 0001191229 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 10,000 shares Expires 2025-05-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The previously granted option, representing a right to purchase a total of 40,000 shares, became exercisable as follows: 25% of the shares subject to the option vested on May 19, 2015, and the balance vested equal installments over the next 24 months. Read SEC document |
| August 01, 2024 Filed Aug 5, 2024 22:39 UTC | REGENXBIO Inc. RGNX · Entity 2211 | Exercise / conversionStock Options (Right to Buy) · Derivative | 100 | $0.00 Strike: $12.74 | $0.00 |
DisclosureSEC source: 0001562180-24-006015 · primarydocument.xml · derivative · entry 6 KARABELAS ARGERIS N · CIK 0001191229 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,400 Underlying: Common Stock · 100 shares Expires 2026-06-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The previously granted option, representing a right to purchase a total of 12,500 shares, became exercisable as follows: the option vested in 12 equal monthly installments following June 1, 2016. Read SEC document |
| August 01, 2024 Filed Aug 5, 2024 22:39 UTC | REGENXBIO Inc. RGNX · Entity 2211 | SaleCommon Stock | 100 | $15.00 | $1,500.00 |
DisclosureSEC source: 0001562180-24-006015 · primarydocument.xml · nonDerivative · entry 5 KARABELAS ARGERIS N · CIK 0001191229 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 11,286 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| August 01, 2024 Filed Aug 5, 2024 22:39 UTC | REGENXBIO Inc. RGNX · Entity 2211 | SaleCommon Stock | 400 | $14.59 | $5,834.00 |
DisclosureSEC source: 0001562180-24-006015 · primarydocument.xml · nonDerivative · entry 4 KARABELAS ARGERIS N · CIK 0001191229 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 11,386 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F3 · price: This transaction was executed in multiple trades at prices ranging from $14.44 to $14.65. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| August 01, 2024 Filed Aug 5, 2024 22:39 UTC | REGENXBIO Inc. RGNX · Entity 2211 | SaleCommon Stock | 9,600 | $13.45 | $129,120.00 |
DisclosureSEC source: 0001562180-24-006015 · primarydocument.xml · nonDerivative · entry 3 KARABELAS ARGERIS N · CIK 0001191229 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 11,786 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $13.20 to $14.05. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| August 01, 2024 Filed Aug 5, 2024 22:39 UTC | REGENXBIO Inc. RGNX · Entity 2211 | Exercise / conversionCommon Stock | 100 | $12.74 | $1,274.00 |
DisclosureSEC source: 0001562180-24-006015 · primarydocument.xml · nonDerivative · entry 2 KARABELAS ARGERIS N · CIK 0001191229 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 21,386 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| August 01, 2024 Filed Aug 5, 2024 22:39 UTC | REGENXBIO Inc. RGNX · Entity 2211 | Exercise / conversionCommon Stock | 10,000 | $3.76 | $37,600.00 |
DisclosureSEC source: 0001562180-24-006015 · primarydocument.xml · nonDerivative · entry 1 KARABELAS ARGERIS N · CIK 0001191229 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 21,286 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| July 29, 2024 Filed Jul 30, 2024 21:01 UTC | REGENXBIO Inc. RGNX · Entity 2211 | Exercise / conversionStock Options (Right to Buy) · Derivative | 11,000 | $0.00 Strike: $12.74 | $0.00 |
DisclosureSEC source: 0001562180-24-005875 · primarydocument.xml · derivative · entry 3 KARABELAS ARGERIS N · CIK 0001191229 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,500 Underlying: Common Stock · 11,000 shares Expires 2026-06-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The previously granted option, representing a right to purchase a total of 12,500 shares, became exercisable as follows: the option vested in 12 equal monthly installments following June 1, 2016. Read SEC document |
| July 29, 2024 Filed Jul 30, 2024 21:01 UTC | REGENXBIO Inc. RGNX · Entity 2211 | SaleCommon Stock | 11,000 | $15.05 | $165,495.00 |
DisclosureSEC source: 0001562180-24-005875 · primarydocument.xml · nonDerivative · entry 2 KARABELAS ARGERIS N · CIK 0001191229 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 11,286 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $15.00 to $15.32. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| July 29, 2024 Filed Jul 30, 2024 21:01 UTC | REGENXBIO Inc. RGNX · Entity 2211 | Exercise / conversionCommon Stock | 11,000 | $12.74 | $140,140.00 |
DisclosureSEC source: 0001562180-24-005875 · primarydocument.xml · nonDerivative · entry 1 KARABELAS ARGERIS N · CIK 0001191229 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 22,286 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| July 01, 2024 Filed Jul 3, 2024 11:55 UTC | REGENXBIO Inc. RGNX · Entity 2211 | Exercise / conversionStock Options (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $3.76 | $0.00 |
DisclosureSEC source: 0001562180-24-005566 · primarydocument.xml · derivative · entry 3 KARABELAS ARGERIS N · CIK 0001191229 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 10,000 shares Expires 2025-05-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The previously granted option, representing a right to purchase a total of 40,000 shares, became exercisable as follows: 25% of the shares subject to this option vested on May 19, 2015, and the balance vested in equal monthly installments over the 24 months thereafter. Read SEC document |
| July 01, 2024 Filed Jul 3, 2024 11:55 UTC | REGENXBIO Inc. RGNX · Entity 2211 | SaleCommon Stock | 10,000 | $11.27 | $112,691.00 |
DisclosureSEC source: 0001562180-24-005566 · primarydocument.xml · nonDerivative · entry 2 KARABELAS ARGERIS N · CIK 0001191229 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 11,286 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $10.98 to $11.76. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| July 01, 2024 Filed Jul 3, 2024 11:55 UTC | REGENXBIO Inc. RGNX · Entity 2211 | Exercise / conversionCommon Stock | 10,000 | $3.76 | $37,600.00 |
DisclosureSEC source: 0001562180-24-005566 · primarydocument.xml · nonDerivative · entry 1 KARABELAS ARGERIS N · CIK 0001191229 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 21,286 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| May 31, 2024 Filed Jun 4, 2024 20:42 UTC | REGENXBIO Inc. RGNX · Entity 2211 | GrantStock Options (Right to Buy) · Derivative | 24,454 | $0.00 Strike: $14.35 | $0.00 |
DisclosureSEC source: 0001562180-24-004654 · primarydocument.xml · derivative · entry 2 KARABELAS ARGERIS N · CIK 0001191229 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,454 Underlying: Common Stock · 24,454 shares Expires 2034-05-31 F2 · derivative.exercise_date: The option will vest in 12 equal monthly installments following May 31, 2024 subject to the continuous service of the optionee to the Issuer. Read SEC document |
| May 31, 2024 Filed Jun 4, 2024 20:42 UTC | REGENXBIO Inc. RGNX · Entity 2211 | GrantCommon Stock | 4,790 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-24-004654 · primarydocument.xml · nonDerivative · entry 1 KARABELAS ARGERIS N · CIK 0001191229 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,286 F1 · shares: Represents shares of common stock underlying a time-based restricted stock unit award (RSU). 100% of the shares subject to this RSU will vest on May 1, 2025 subject to the continuous service of the recipient to the Issuer. Read SEC document |
| June 02, 2023 Filed Jun 6, 2023 21:12 UTC | REGENXBIO Inc. RGNX · Entity 2211 | GrantStock Options (Right to Buy) · Derivative | 17,892 | $0.00 Strike: $19.72 | $0.00 |
DisclosureSEC source: 0001562180-23-004890 · primarydocument.xml · derivative · entry 2 KARABELAS ARGERIS N · CIK 0001191229 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,892 Underlying: Common Stock · 17,892 shares Expires 2033-06-02 F2 · derivative.exercise_date: The option will vest in 12 equal monthly installments following June 2, 2023 subject to the continuous service of the optionee to the Issuer. Read SEC document |
| June 02, 2023 Filed Jun 6, 2023 21:12 UTC | REGENXBIO Inc. RGNX · Entity 2211 | GrantCommon Stock | 3,486 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-23-004890 · primarydocument.xml · nonDerivative · entry 1 KARABELAS ARGERIS N · CIK 0001191229 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,496 F1 · shares: Represents shares of common stock underlying a time-based restricted stock unit award (RSU). 100% of the shares subject to this RSU will vest on June 1, 2024 subject to the continuous service of the recipient to the Issuer. Read SEC document |
| June 24, 2022 Filed Jun 28, 2022 20:38 UTC | Bausch Health Companies Inc. BHC · Entity 4363 | GrantCommon Shares, No Par Value | 34,387 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-018201 · form4.xml · nonDerivative · entry 1 KARABELAS ARGERIS N · CIK 0001191229 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 123,715 F1 · shares: Represents the award of restricted share units ("RSUs") granted to non-employee directors of the Issuer on the third business day following their election at the Issuer's Annual Meeting of Shareholders. The RSUs have a grant date value equal to $250,000, vest immediately prior to the Issuer's next Annual Meeting of Shareholders, and are settled in common shares, no par value, of the Issuer. Read SEC document |
| June 03, 2022 Filed Jun 7, 2022 20:20 UTC | REGENXBIO Inc. RGNX · Entity 2211 | GrantStock Option (Right to Buy) · Derivative | 15,324 | $0.00 Strike: $22.84 | $0.00 |
DisclosureSEC source: 0001562180-22-004878 · primarydocument.xml · derivative · entry 2 KARABELAS ARGERIS N · CIK 0001191229 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,324 Underlying: Common Stock · 15,324 shares Expires 2032-06-03 F2 · derivative.exercise_date: The option will vest in 12 equal monthly installments following June 3, 2022 while the optionee provides continuous service to the Issuer. Read SEC document |
| June 03, 2022 Filed Jun 7, 2022 20:20 UTC | REGENXBIO Inc. RGNX · Entity 2211 | GrantCommon Stock | 3,010 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-22-004878 · primarydocument.xml · nonDerivative · entry 1 KARABELAS ARGERIS N · CIK 0001191229 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,010 F1 · shares: Represents shares of common stock underlying a time-based restricted stock unit award (RSU). 100% of the shares subject to this RSU will vest on June 1, 2023 while the recipient provides continuous service to the Issuer. Read SEC document |
| June 04, 2021 Filed Jun 8, 2021 20:20 UTC | REGENXBIO Inc. RGNX · Entity 2211 | GrantStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $35.52 | $0.00 |
DisclosureSEC source: 0001562180-21-004129 · primarydocument.xml · derivative · entry 1 KARABELAS ARGERIS N · CIK 0001191229 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2031-06-04 F1 · derivative.exercise_date: The option will vest in 12 equal monthly installments following June 4, 2021. Read SEC document |
| April 30, 2021 Filed May 3, 2021 20:07 UTC | Bausch Health Companies Inc. BHC · Entity 4363 | GrantCommon Shares, No Par Value | 7,645 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-014909 · form4.xml · nonDerivative · entry 1 KARABELAS ARGERIS N · CIK 0001191229 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89,328 F1 · shares: Represents the award of restricted share units ("RSUs") granted to non-employee directors of the Issuer on the third business day following their election at the Issuer's Annual Meeting of Shareholders. The RSUs have a grant date value equal to $250,000, vest immediately prior to the Issuer's next Annual Meeting of Shareholders, and are settled in common shares, no par value, of the Issuer. Read SEC document |
| May 29, 2020 Filed Jun 2, 2020 20:35 UTC | REGENXBIO Inc. RGNX · Entity 2211 | GrantStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $37.66 | $0.00 |
DisclosureSEC source: 0001562180-20-004069 · primarydocument.xml · derivative · entry 1 KARABELAS ARGERIS N · CIK 0001191229 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2030-05-29 F1 · derivative.exercise_date: The option will vest in 12 equal monthly installments following May 29, 2020. Read SEC document |
| May 01, 2020 Filed May 1, 2020 20:15 UTC | Bausch Health Companies Inc. BHC · Entity 4363 | GrantCommon Shares, No Par Value | 11,037 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-015029 · form4.xml · nonDerivative · entry 1 KARABELAS ARGERIS N · CIK 0001191229 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,683 F1 · shares: Represents the award of restricted share units ("RSUs") granted to non-employee directors of the Issuer on the third business day following their election at the Issuer's Annual Meeting of Shareholders. The RSUs have a grant date value equal to $200,000, vest immediately prior to the Issuer's next Annual Meeting of Shareholders, and are settled in common shares, no par value, of the Issuer. Read SEC document |
| May 31, 2019 Filed Jun 4, 2019 20:22 UTC | REGENXBIO Inc. RGNX · Entity 2211 | GrantStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $43.02 | $0.00 |
DisclosureSEC source: 0001562180-19-003295 · primarydocument.xml · derivative · entry 1 KARABELAS ARGERIS N · CIK 0001191229 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2029-05-31 F1 · derivative.exercise_date: The option will vest in 12 equal monthly installments following May 31, 2019. Read SEC document |
| May 03, 2019 Filed May 3, 2019 20:14 UTC | Bausch Health Companies Inc. BHC · Entity 4363 | GrantCommon Stock, No Par Value | 10,633 | $23.51 | $249,981.83 |
DisclosureSEC source: 0001127602-19-017262 · form4.xml · nonDerivative · entry 1 KARABELAS ARGERIS N · CIK 0001191229 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,646 F1 · shares: Represents the award of restricted share units ("RSUs") granted to non-employee directors of Bausch Health Companies Inc. ("Bausch Health") on the third business day following their election at the Annual Meeting of Shareholders of Bausch Health (the "Annual Meeting"). The RSUs have a grant date value equal to $250,000, vest immediately prior to Bausch Health's next Annual Meeting, and are settled in common shares, no par value, of Bausch Health. Read SEC document |
| May 25, 2018 Filed May 30, 2018 20:47 UTC | REGENXBIO Inc. RGNX · Entity 2211 | GrantStock Option (Right to Buy) · Derivative | 12,500 | $0.00 Strike: $49.45 | $0.00 |
DisclosureSEC source: 0001562180-18-002721 · primarydocument.xml · derivative · entry 1 KARABELAS ARGERIS N · CIK 0001191229 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 12,500 shares Expires 2028-05-25 F1 · derivative.exercise_date: The option will vest in 12 equal monthly installments following May 25, 2018. Read SEC document |
| May 03, 2018 Filed May 4, 2018 21:54 UTC | Bausch Health Companies Inc. VRX · Entity 4363 | GrantCommon Stock, No Par Value | 14,285 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-016406 · form4.xml · nonDerivative · entry 1 KARABELAS ARGERIS N · CIK 0001191229 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,417 F1 · shares: Represents the award of restricted share units ("RSUs") granted to non-employee directors of Valeant Pharmaceuticals International, Inc. ("Valeant") on the third business day following their election at the Annual Meeting of Shareholders of Valeant (the "Annual Meeting"). The RSUs have a grant date value equal to $250,000, vest immediately prior to Valeant's next Annual Meeting, and are settled in common shares, no par value, of Valeant. Read SEC document |
| May 03, 2018 Filed May 8, 2018 20:34 UTC Amendment | Bausch Health Companies Inc. VRX · Entity 4363 | GrantCommon Stock, No Par Value | 13,881 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-016650 · form4a.xml · nonDerivative · entry 1 KARABELAS ARGERIS N · CIK 0001191229 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,013 F1 · shares: Represents the award of restricted share units ("RSUs") granted to non-employee directors of Valeant Pharmaceuticals International, Inc. ("Valeant") on the third business day following their election at the Annual Meeting of Shareholders of Valeant (the "Annual Meeting"). The RSUs have a grant date value equal to $250,000, vest immediately prior to Valeant's next Annual Meeting, and are settled in common shares, no par value, of Valeant. F2 · shares: This Amended Form 4 is being filed to correct the number of RSUs acquired on May 3, 2018 as reported on the Form 4 filed on May 4, 2018. Read SEC document |
| May 24, 2017 Filed May 26, 2017 21:00 UTC | REGENXBIO Inc. RGNX · Entity 2211 | GrantStock Option (Right to Buy) · Derivative | 12,500 | $0.00 Strike: $18.85 | $0.00 |
DisclosureSEC source: 0000899243-17-014566 · doc4.xml · derivative · entry 1 KARABELAS ARGERIS N · CIK 0001191229 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 12,500 shares Expires 2027-05-24 F1 · derivative.exercise_date: The option will vest in 12 equal monthly installments following May 24, 2017. Read SEC document |
| May 05, 2017 Filed May 5, 2017 21:22 UTC | Bausch Health Companies Inc. VRX · Entity 4363 | GrantCommon Stock, no par value | 25,406 | $0.00 | $0.00 |
DisclosureSEC source: 0000885590-17-000028 · primary_doc.xml · nonDerivative · entry 1 KARABELAS ARGERIS N · CIK 0001191229 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,132 F1 · shares: Regular annual Restricted Share Units (RSUs) equal to $250,000 granted to non-employee directors in office on the third trading day following the Annual Meeting of Shareholders based on the closing price of registrant common stock on the date prior to the grant. RSUs represent a contingent right to receive one share of common stock, no par value, of Valeant Pharmaceuticals International, Inc. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.